Qube Research & Technologies LTD Ngm Biopharmaceuticals Inc Transaction History

Qube Research & Technologies LTD

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 13, 2024	SELL	$0.6 - $1.31 $9,725 - $21,233	-16,209 Reduced 97.69%	384 $0
Q3 2023 Nov 13, 2023	SELL	$1.05 - $3.37 $47,275 - $151,730	-45,024 Reduced 73.07%	16,593 $17,000
Q2 2023 Aug 14, 2023	BUY	$2.44 - $4.53 $70,220 - $130,368	28,779 Added 87.64%	61,617 $159,000
Q1 2023 May 15, 2023	SELL	$3.72 - $5.4 $16,248 - $23,587	-4,368 Reduced 11.74%	32,838 $133,000
Q4 2022 Feb 14, 2023	BUY	$3.41 - $12.93 $126,872 - $481,073	37,206 New	37,206 $186,000
Q3 2020 Nov 12, 2020	SELL	$15.59 - $19.97 $615,368 - $788,255	-39,472 Closed	0 $0
Q2 2020 Aug 14, 2020	BUY	$11.97 - $23.47 $472,479 - $926,407	39,472 New	39,472 $779,000

2.6M

300

Ticker NGM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 80,365,904
Description
NGM Biopharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of novel therapeutics to treat liver and metabolic diseases, retinal diseases, and cancer. The company's product candidates include Aldafermin, an engineered analog of human hormone fibroblast growth factor 19, which is in Phase IIb clinical trial...

Get notified when there are updates to the investment portfolio of Qube Research & Technologies LTD, based on Form 13F filings with the SEC.

Stay updated on Qube Research & Technologies LTD with notifications on news.